DDInter132 DDInter1676
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Atomoxetine {u} (Compound) resembles {v} (Compound) Benzatropine
Atomoxetine {u} (Compound) resembles {v} (Compound) Fenoprofen
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Atomoxetine {u} (Compound) binds {v} (Gene) HTR2C
Atomoxetine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Atomoxetine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Atomoxetine {u} (Compound) downregulates {v} (Gene) FABP5
Atomoxetine {u} (Compound) causes {v} (Side Effect) Depressive symptom
Atomoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Atomoxetine (Compound) resembles Benzatropine (Compound)
Atomoxetine (Compound) resembles Fenoprofen (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Atomoxetine (Compound) binds HTR2C (Gene)
Atomoxetine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Atomoxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Atomoxetine (Compound) downregulates FABP5 (Gene)
Atomoxetine (Compound) causes Depressive symptom (Side Effect)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix